Clarivate Shares Rise After $600M Sale of Life Sciences Unit; Debt Reduction in Focus
Clarivate rose in pre-market trading after announcing a definitive agreement to sell its Life Sciences & Healthcare business to Altaris LLC for $600 million. The proceeds will be used to retire notes maturing in 2028 and 2029, and management expects the divestiture to improve recurring revenue mix, expand Adjusted EBITDA margins, and reduce capital…